$LKFT News
Last published 3h ago
- 3h agoLKFTLakefront Biotherapeutics Reports Nine Months 2026 Financial Results and Provides Business UpdateGlobeNewswireGamgertamig poster accepted for presentation at the 2026 ASH 1 Annual Meeting, featuring data from ongoing Phase 1b studies that suggest potential to retain remission after B cell reconstitution, maintained in the absence of background therapy for autoimmune cytopenias, consistent with an “immune reset”
- 1d agoLKFTLakefront to Present at the 2026 Jefferies Global Healthcare Conference in LondonGlobeNewswireMechelen, Belgium; November 10, 2026, 22.01 CET; Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced that the Company will host a fireside chat at the 2026 Jefferies Global Healthcare Conference in London at 2:00 pm GMT (9:00 am ET) on Tuesday, November 17, 2026.
- 1w agoLKFTLakefront Biotherapeutics Announces Poster Presentation at the 2026 American Society of Hematology MeetingGlobeNewswireGamgertamig data from ongoing Phase 1b studies suggest potential to retain remission after B cell reconstitution, maintained in the absence of background therapy for autoimmune cytopenias, consistent with an "immune
- 1w agoLKFTLakefront Biotherapeutics Welcomes Dr. Mehdi Shahidi to its Board of DirectorsGlobeNewswireDr. Shahidi brings extensive drug development experience, regulatory success, and transformative operational expertise to the Board Mechelen, Belgium; November 2, 2026, 22.01 CET; Lakefront Biotherapeutics NV
- 4w agoLKFTLakefront Announces Sale of Preclinical CAR-T Programs to Armed Cell TherapeuticsGlobeNewswirePreviously announced wind-down of the legacy cell therapy activities is substantially complete Mechelen, Belgium; October 14, 2026, 22.01 CEST; Lakefront Biotherapeutics NV ((Euronext &, NASDAQ:LKFT) today
- 1mo agoLKFTLakefront Receives Transparency Notification from Bank of AmericaGlobeNewswireMechelen, Belgium; October 8, 2026, 22.01 CET; regulated information – Lakefront Biotherapeutics NV ((Euronext &, NASDAQ:LKFT) received a transparency notification from Bank of America. Pursuant to Belgian
- 1mo agoGLPGLKFT1773831 - LAKEFRONT BIOTHERAPEUTICS NVEarnings Call TranscriptsGood afternoon, everyone. Welcome to the final fireside of day two at Morgan Stanley's Global Healthcare Conference. I'm Judah Frommer, one of the SMID biotech analysts here. We're very excited to have Henry, Aaron, and
- 2mo agoLKFTAcquisition of Own SharesGlobeNewswireMechelen, Belgium; 08 September 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV ((Euronext &, NASDAQ:LKFT)
- 2mo agoLKFTLakefront to Present at the Morgan Stanley 24th Annual Global Healthcare ConferenceGlobeNewswireMechelen, Belgium; 8 September 2026, 22.01 CET; Lakefront Biotherapeutics NV ((Euronext &, NASDAQ:LKFT) today announced that the Company will host a fireside chat at the Morgan Stanley 24th Annual Global Healthcare
- 2mo agoLKFTLakefront Receives Transparency Notification from Bank of AmericaGlobeNewswireMechelen, Belgium; August 24, 2026, 22.01 CET; regulated information – Lakefront Biotherapeutics NV ((Euronext &, NASDAQ:LKFT) received a transparency notification from Bank of America. Pursuant to Belgian
- 2mo agoLKFTU.S. FDA Grants Orphan Drug Designation to Gamgertamig for the Treatment of PemphigusGlobeNewswireMechelen, Belgium; 24 August 2026, 22.01 CET; regulated information – Lakefront Biotherapeutics NV ((Euronext &, NASDAQ:LKFT) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug
- 2mo agoLKFTKeymed Biosciences Announces 2026 H1 Results and Business UpdatesPR NewswireOn August 19, 2026, Keymed Biosciences (HKEX: 02162) announced its interim results for the six months ended June 30, 2026. Guided by a clear...
- 3mo agoLKFTAcquisition of Own SharesGlobeNewswireMechelen, Belgium; 12 August 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV ((Euronext &, NASDAQ:LKFT)
- 3mo agoLKFTLakefront Biotherapeutics Reports Half-Year 2026 Financial Results and Provides Business UpdateGlobeNewswireCompleted acquisition of Ouro Medicines with Gilead Sciences to advance potential first and best-in-class T-cell engager Forecast at least €1.6B of cash remaining after funding portfolio to first gamgertamig approval
- 4mo agoLKFTLakefront Announces Paulo Fontoura has Resigned from its Board following his Appointment as Global Head of R&D at SanofiGlobeNewswireMechelen, Belgium; July 13, 2026, 22:01 CET; Lakefront Biotherapeutics NV ((Euronext &, NASDAQ:LKFT) today announced that following his appointment as Executive Vice President, Global Head of Research &
- 4mo agoLKFTLakefront Receives Transparency Notification from Madison Avenue PartnersGlobeNewswireMechelen, Belgium; June 29, 2026, 22.01 CET; regulated information – Lakefront Biotherapeutics NV ((Euronext &, NASDAQ:LKFT) received a transparency notification from Madison Avenue Partners. Pursuant to Belgian
- 4mo agoLKFTAcquisition of Own SharesGlobeNewswireMechelen, Belgium; June 16, 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV ((Euronext &, NASDAQ:LKFT)
- 5mo agoLKFTLakefront Announces Initiation of €50 Million Stock Repurchase ProgramGlobeNewswireMechelen, Belgium; June 9, 2026, 22:01 CET; regulated information – Lakefront Biotherapeutics NV ((Euronext &, NASDAQ:LKFT) today announced the launch of a share repurchase program (the "Program"), under which the
- 5mo agoLKFTLakefront Appoints Eric Hedrick, MD, as Chief Medical OfficerGlobeNewswireMechelen, Belgium; June 8, 2026, 22:01 CET; Lakefront Biotherapeutics NV ((Euronext &, NASDAQ:LKFT) today announced that Eric Hedrick, MD has been appointed Chief Medical Officer. This expanded leadership role
- 5mo agoGILDLKFTGILEAD SCIENCES AND LAKEFRONT COMPLETE ACQUISITION OF OURO MEDICINES TO FURTHER EXPAND INFLAMMATION PIPELINEGlobeNewswireCompanies will collaborate on the development of gamgertamig, a potential first-in-class and best-in-class T cell engager in autoimmune diseases Foster City, Calif. and Mechelen, Belgium; June 4, 2026, 22.15 CET –
- 5mo agoGILDLKFTGilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation PipelineBusiness Wire– Companies will collaborate on the development of gamgertamig, a potential first-in-class and best-in-class T cell engager in autoimmune diseases – Gilead Sciences, Inc. (NASDAQ:GILD) and Lakefront Biotherapeutics NV
- 5mo agoLKFTLakefront Receives Transparency Notification from Bank of AmericaGlobeNewswireMechelen, Belgium; May 26, 2026, 22.01 CET; regulated information – Lakefront Biotherapeutics NV ((Euronext &, NASDAQ:LKFT) received a transparency notification from Bank of America. Pursuant to Belgian transparency
- 8mo agoGLPGLKFTLEERINK GLOBAL HEALTHCARE CONFERENCE - LAKEFRONT BIOTHERAPEUTICS NVEarnings Call TranscriptsI think it's the morning. Good morning, everyone. This is Dana Graybosch. I'm a senior equity research analyst here at Lyric Partners, and I'm excited to be hosting management from Gilead this morning. We have Dietmar an
- 8mo agoGLPGLKFTTD Cowen 46th Annual Health Care Conference - LAKEFRONT BIOTHERAPEUTICS NVEarnings Call TranscriptsThat's exciting. All right. Good morning, everyone. Tyler Van Buren here, Senior Biotech Analyst at TD Cowan. Thank you very much for joining TD Cowans' 46th Annual Healthcare Conference. For our next session, it's a pri